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DCABG procedures during the study time frame. Therefore,
no conclusions can be drawn for female patients. However,
this study reflects the typical cardiac surgical practice for
most VA-based surgeons across different VA medical cen-
ters, given the diversity of POAF-related practice patterns
reported. Because such no statements can be made regard-
ing the wide range of POAF seen among the participating
centers, these findings are in contradistinction to other pub-
lished smaller series reported by a single surgeon or a single
institution, where the single-center’s data may not be
broadly generalizable to a community practice setting.References
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Dr David McGiffin (Birmingham, Ala). The investigators in
the ROOBY trial and the authors of this substudy are to be congrat-
ulated for taking on this important project, the results of which will
be of benefit to all of us.
At first glance, this study would seem to be straightforward.
However, in reality, it does have a number of methodological
and analytic conundrums, and I would like you to respond to a cou-
ple of concerns that I have, and we will deal with them one at
a time.
My first concern is about the relationship between postoperative
AF and the early postoperative outcome events that you examined,
including reintubation and renal failure. The use of the phrase
‘‘impact of postoperative atrial fibrillation on outcomes,’’ which
appears in the abstract, and the word ‘‘impact,’’ which appears
in your title, implies cause and effect. However, as far as I can
see from the presentation, it is possible that the outcome event
may have occurred before the episode of postoperative AF, and
furthermore, postoperative AF is frequently part of the clinical pre-
sentation of a number of outcome events, including respiratory
failure. Are you implying cause and effect, and if so, could you
reconcile the inference of cause and effect with the realities of
the study?
Dr Almassi. In regard to the cause and effect, it is really diffi-
cult, like the chicken and egg question, which one came first, but in
terms of the incidence of AF, we have the occurrences, as I showed
here, when it occurred. But in terms of the AF, I don’t have the data
to show when, for example, renal failure developed. However, the
reintubation and mechanical support, prolonged mechanical sup-
port beyond 48 hours, would indicate that AF probably happened
earlier, but I don’t have the data to show that that is in fact the case.
Because the patients were similar in baseline characteristics at ran-
domization, it would seem that postoperative AF may be the cause
rather than the effect, although, as I said, with the data as they are, I
cannot state with certainty that is the case.
Dr McGiffin. So my summary of that would be that before
claiming cause and effect or impact, this would require consider-
ably more analysis?
Dr Almassi. We can certainly see association. I agree with you.
DrMcGiffin.Another concern is the suggestion from your pre-
sentation that the occurrence of postoperative AF is a determinant
of survival 12 months after operation, which is implied from your
Kaplan–Meier curves of survival, stratified by the presence or ab-
sence of postoperative AF. I think one could fairly ask the question,
what does 30 minutes of postoperative AF have to do with in-
creased probability of dying over the next 12 months? An alterna-
tive explanation is that postoperative AF is really amarker for an as
yet unidentified cause of death. I think that before concluding that
the occurrence of postoperative AF directly and adversely affects
survival 12 months after surgery, a thorough investigation of the
late causes of death and their relationship to postoperative AF
would need to be undertaken. If you are hypothesizing a cause-
and-effect relationship between postoperative AF and latery c January 2012
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Dmortality, do you have the information about late causes of death
that would lead you to this inference?
Dr Almassi.We do not have the causes of late death. However,
we did a number of multivariate analyses in terms of the different
effects, such as the cardiopulmonary bypass circuit and the inter-
action between the technique of surgery versus other factors, and
in all of these, AF stood out as the significant factor rather than
other causes. However, because we do not have the exact cause
of death in the patients who died, I could not give an answer in
terms of why they died.
However, the available information in the literature, which is
mainly from retrospective analysis and some data from Italy on au-
topsy of patients who died postoperatively in AF, indicates that
most of the deaths in those retrospective studies were cardiac.
DrMcGiffin. So perhaps it would be fair to say that we need to
temper the inference that there is a cause-and-effect relationship
between early postoperative AF and late mortality at this stage?
Dr Almassi. Yes.
Dr McGiffin. Finally, I think you have put to rest the idea that
postoperative AF is caused by purely atrial cannulation for cardio-
pulmonary bypass and the consequences of myocardial protection
in the ONCAB group. One possible mechanism of postoperative
AF that is common to both the ONCAB and OPCAB techniques
is pericardial inflammation. Now, this would seem to have support
from animal models in which AF can be readily induced by peri-
cardial inflammation and the known efficacy of corticosteroids in
preventing postoperative AF.
In light of your findings, what are your thoughts on the mecha-
nism of postoperative AF and are there perioperative measures that
you would recommend to reduce the incidence of postoperative
AF?
Dr Almassi.We do not know the exact mechanism of postoper-
ative AF. There are no available studies that have shown that.
Therefore, any strategies that have been used—and there is plenty
of information in the literature on various strategies, atrial pacing,
as we yesterday heard about biatrial pacing, different medications
that are used, method of use of medication, length of preoperative
use, and intra- and postoperative use—everything has been tried,
and none have proven successful in preventing postoperative AF.
In our analysis we have looked at the perioperative use of antiar-
rhythmic medications, and that did not seem to have an impact
on the postoperative AF incidence. As you mentioned, cardiopul-
monary bypass and the method of myocardial preservation in the
ONCAB group did not have any effect on the rate of AF. So I
am not sure that I have any strategy to prevent postoperative AF
at this time.
Dr Niv Ad (Falls Church, Va). I have 2 issues that I believe
would require clarifications. The definition of AF as an event of
30 minutes or longer is unique. Can you tell us how did you decide
to define it in such a way? It is hard to believe that a short event
would have an impact and 30 minutes can’t be compared with 1
hour and longer.
The second comment I have is related to your conclusions with
regard to the future treatment of POAF. It seams to me that the dataThe Journal of Thoracic and Cshould be analyzed further because some of centers had only an ap-
proximately 10% rate of postoperative AF, whereas the others had
more than 30%. This leads to a potential bias in which not all cen-
ters treated their patients the same and the management of perio-
perative antiarrhythmic drugs across all centers was different?
Dr Almassi. No, it was not. Every center for the 2 groups in the
study used their standard of care at each center. That doesn’t mean
that all centers used the same protocol, no.
In terms of the incidence of AF, as I showed among centers here,
it was from 12.14% to 35%. Some of the reported incidences de-
pend on the method of monitoring patients and the extent of mon-
itoring. If a patient is only monitored in the intensive care unit and
then on the stepdown or telemetry unit, there is no monitoring, just
relied on physical examination and an occasional electrocardio-
gram, clearly the incidence of postoperative AF is going to be
underestimated. To enter into the study in terms of following pa-
tients with AF, we used a minimum of 30 minutes being in AF.
That doesn’t mean that patients converted to sinus rhythm imme-
diately. We didn’t want to include any patients who developed AF
for 1 or 2 minutes to be included in this study. Therefore, we used
that definition, more than 30 minutes.
Dr Ad. Okay, thank you, but I believe that you should include
those 2 points in your study limitations.
Dr Almassi. Okay.
Dr Richard Shemin (Los Angeles, Calif). I want to echo the
concerns that Dr Ad brought up, the variation in preoperative pro-
phylaxis and the variation in the study from 10% to 30%. Again, I
am concerned about the definition. We are measuring a postopera-
tive outcome of AF, and I am still not sure what 30 minutes of AF
means. If someone goes into AF in the intensive care unit or on the
floor and they get amiodarone and they convert within 10 minutes,
does that mean they did not have AF?
Dr Almassi. For the study, that doesn’t mean they didn’t have
AF. Yes, they did. But to include them in this study for the sake
of follow-up, we picked 30 minutes. You can pick a minute or
any episode of AF. For this study, for the numbers that we have,
which is large enough, those patients who had AF were similar
at baseline and after randomization, but the outcome was not as
good as the patients with no postoperative AF. That is the message
that our data show.
Dr Frank Baciewicz (Detroit, Mich). The Society of Thoracic
Surgery in Michigan looks at all the differences between hospitals,
and one of the things they look at is AF, which has been looked at
carefully. We have not been able to glean out any differences in
why one hospital has a 10% and one has a 30% rate of AF. Have
you been able to glean that out? I knowyoumentioned that themon-
itoring certainly makes a difference, and our data were looked at
carefully and we can’t seem to find anything. Could you find any
difference between the hospitals to explain this variation?
Dr Almassi. I don’t have those data, no. But when we looked at
each individual hospital, there was no difference in AF between
the patients who underwent OPCAB versus the on-pump group.
That we know. But in terms of the practice for each individual hos-
pital, I don’t have those data, no.ardiovascular Surgery c Volume 143, Number 1 99
